BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN - News) (www.regenerx.com) announced today that it has received official notice from Chinese Patent Office (CSIPO) that CSIPO intends to grant a patent for reversing or inhibiting eye degeneration associated with dry eye syndrome, as well as certain surgical eye procedures, including LASIK and PRK, with Tß4, analogues, and derivatives. The patent claims are based on a significant body of data supporting the use of Tß4 for wound healing of the cornea and other areas in and around the eye.
